Design, Synthesis and Structure of Peptides and Proteins news

28 Oct 2009

Diario Médico explains the research line followed by the lab led by Ernest Giralt, head of the Chemistry and Molecular Pharmacology Programme at IRB Barcelona, on a peptide that inhibits aggregation of the beta amyloid protein, a characteristic of Alzheimer’s disease. Giralt has presented the results of his study in the Barcelona BioMed Conference entitle “Engineering peptides”, organized by IRB Barcelona and the BBVA Foundation.

<p>3D simulation on the interaction between a therapeutic peptide and the beta amyloid fibrils formed in Alzheimer's disease (© Ernest Giralt, IRB Barcelona)</p>
22 Oct 2009

IRB Barcelona and the BBVA Foundation invite twenty international experts in therapeutic peptide engineering to a Barcelona BioMed Conference, which will be held in Barcelona from 26 to 28 October.

<p>Different stages during the process of amyloid fibril formation<br /> (A)Electron microscope images after 2, 6 and 21 days of aggregation <br />(B)Atomic force microscope images after 3 and 21 days of aggregation</p>
30 Apr 2009

This breakthrough is crucial as recent studies demonstrate that there is a correlation between the severity of these diseases and the intermediates formed during the process of amyloid fibril formation.